Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Simulations Plus Inc.

    NASDAQ: SLP · Real-Time Price · USD
    32.13
    0.32 (1.01%)
    At close: May 29, 2025, 3:59 PM
    32.17
    0.11%
    After-hours: May 29, 2025, 04:04 PM EDT
    1.01%
    Bid 29.2
    Market Cap 646.27M
    Revenue (ttm) 78.56M
    Net Income (ttm) 7.22M
    EPS (ttm) 0.36
    PE Ratio (ttm) 89.26
    Forward PE 25.48
    Analyst Buy
    Ask 33.9
    Volume 89,645
    Avg. Volume (20D) 318,359
    Open 32.01
    Previous Close 31.81
    Day's Range 31.95 - 32.51
    52-Week Range 23.01 - 50.11
    Beta 1.10

    About SLP

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol SLP
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for SLP stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    1 month ago
    +26.85%
    Shares of healthcare technology stocks are trading... Unlock content with Pro Subscription
    1 month ago
    +0.74%
    Simulations Plus shares are trading higher. The stock may be moving up after the FDA stated plans to phase out animal testing requirements for monoclonal antibodies and other drugs.
    news image

    1 week ago · zacks.com

    SLP Advances Predictive Toxicology With DILIsym 11: Shares to Benefit?

    Simulations Plus unveils DILIsym 11, an upgraded version of its flagship QST platform to advance predictive toxicology and pediatric liver assessment safety.

    news image

    2 weeks ago · businesswire.com

    Simulations Plus Releases DILIsym® 11

    RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intel...

    news image

    1 month ago · businesswire.com

    Simulations Plus Supports New FDA Roadmap for Reducing Animal Testing in Preclinical Safety Studies

    RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intel...

    news image

    1 month ago · seekingalpha.com

    Simulations Plus: Benefiting From FDA Modernization And AI

    Simulations Plus, Inc. offers AI-based software tools for drug discovery and optimization, significantly reducing R&D time and costs for pharmaceutical research. SLP's diverse software portfolio, incl...

    news image

    1 month ago · benzinga.com

    What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday?

    The U.S. Food and Drug Administration announced a major shift in how monoclonal antibody therapies and other drugs are evaluated, emphasizing a transition from traditional animal testing.

    news image

    1 month ago · seekingalpha.com

    Simulations Plus: I See Promising Growth, But I'm Staying Neutral

    Simulations Plus, Inc. excels with its AI-driven biosimulation platforms, aiding drug development, but faces challenges with margin erosion and cash flow pressures. Despite strong revenue growth and p...

    news image

    1 month ago · zacks.com

    SLP's Q2 Earnings Top, Sales Up Y/Y Despite Industry Headwinds

    Simulations Plus' fiscal Q2 2025 performance gains from its strong software solutions and services portfolio amid limited customer funding.

    news image

    1 month ago · seekingalpha.com

    Simulations Plus, Inc. (SLP) Q2 2025 Earnings Call Transcript

    Simulations Plus, Inc. (NASDAQ:SLP ) Q2 2025 Earnings Conference Call April 3, 2025 5:00 PM ET Company Participants Lisa Fortuna - IR, Financial Profiles Shawn O'Connor - CEO Will Frederick - CFO & CO...

    news image

    1 month ago · zacks.com

    Simulations Plus (SLP) Tops Q2 Earnings and Revenue Estimates

    Simulations Plus (SLP) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.20 per share a year ago.

    news image

    1 month ago · businesswire.com

    Simulations Plus Reports Second Quarter Fiscal 2025 Financial Results

    RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intel...

    Add to Watchlist